Source: PR Newswire
Elanco Animal Health has launched a major restructuring plan that will eliminate around 600 positions worldwide, including roughly 300 layoffs and 300 role or location shifts. The initiative, known as “Elanco Ascend,” is aimed at reducing operating costs and generating significant long-term savings beginning in 2026. As part of the restructuring, the company will close a manufacturing facility in Germany and expand research and development operations in Indianapolis, reshaping its global footprint to better support future growth.
Although the company expects to incur a substantial restructuring charge of about $175 million, Elanco says the changes are intended to enhance efficiency, streamline operations, and strengthen its ability to advance its animal-health product pipeline. Leadership emphasized that the moves position the organization for improved competitiveness and sustainable growth as it refocuses resources on priority areas.